Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.

Qilai LongAi-Hong MaHongyong ZhangZhixiu CaoRoger XiaTzu-Yin LinGuru P SonpavdeRalph de Vere WhiteJianming GuoChong-Xian Pan

Published in: Cancer immunology, immunotherapy : CII (2020)

The CDK4/6 pathway is feasible as a potential target for the treatment of bladder cancer, especially in combination with immunotherapy. A CDK4/6 inhibitor should not be combined with gemcitabine.

Keyphrases

cell cycle
combination therapy
cell death
risk assessment
cell proliferation
tyrosine kinase
replacement therapy
smoking cessation